After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

London based biotech Motif Bio PLC (LON:MTFB) just filed for a NASDAQ listing by way of an IPO in the US, and it’s drawing quite a lot of attention in the infectious disease space. The company’s ...

Health-care shares were mainly unchanged in pre-market trade on Tuesday. In health-care stocks news, Motif Bio plc ( MTFB) said Tuesday that REVIVE-1, the company's global phase 3 clinical trial of ...

Discussion: FDA accepted for filing the NDA of Motif Bio’s (MTFB) iclaprim. Iclaprim is a gram-positive investigational antibiotic, targeted for the treatment of acute bacterial skin and skin ...

Motif Bio Plc (MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel ...

Four companies are listed on this week's upcoming IPO calendar. According to Renaissance Capital, which manages IPO-focused ETFs, the four new IPOs this week are set to raise $270 million in proceeds.

Motif Bio, which is developing novel antibiotics effective against multi-drug resistant bacteria, filed on Wednesday with the SEC to raise up to $40 million in an initial public offering. The company ...